DDInter148 DDInter1676
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and inhibiting protein and DNA synthesis. The other one is through the inhibition of DNA methyltransferase, impairing DNA methylation. Due to its anti-neoplastic activity and its ability to inhibit methylation in replicating DNA, azacytidine has been used mainly used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), two types of cancer characterized by the presence of aberrant DNA methylation.[
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Azacitidine {u} (Compound) resembles {v} (Compound) Adenosine
Azacitidine {u} (Compound) resembles {v} (Compound) S-Adenosylmethionine
Azacitidine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Azacitidine {u} (Compound) binds {v} (Gene) DNMT3A
Azacitidine {u} (Compound) upregulates {v} (Gene) FOXJ3
Azacitidine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Azacitidine {u} (Compound) downregulates {v} (Gene) ANXA2
Azacitidine {u} (Compound) causes {v} (Side Effect) Neck pain
Azacitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Azacitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Azacitidine (Compound) resembles Adenosine (Compound)
Azacitidine (Compound) resembles S-Adenosylmethionine (Compound)
Azacitidine may lead to a major life threatening interaction when taken with Cladribine
Azacitidine (Compound) binds DNMT3A (Gene)
Azacitidine (Compound) upregulates FOXJ3 (Gene)
Azacitidine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Azacitidine (Compound) downregulates ANXA2 (Gene)
Azacitidine (Compound) causes Neck pain (Side Effect)
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab